EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
- Smolen, J.S.
- Landewe, R.B.M.
- Bergstra, S.A.
- Kerschbaumer, A.
- Sepriano, A.
- Aletaha, D.
- Caporali, R.
- Edwards, C.J.
- Hyrich, K.L.
- Pope, J.E.
- Souza, S. de
- Stamm, T.A.
- Takeuchi, T.
- Verschueren, P.
- Winthrop, K.L.
- Balsa, A.
- Bathon, J.M.
- Buch, M.H.
- Burmester, G.R.
- Buttgereit, F.
- Cardiel, M.H.
- Chatzidionysiou, K.
- Codreanu, C.
- Cutolo, M.
- Broeder, A.A. den
- Aoufy, K. el
- Finckh, A.
- Fonseca, J.E.
- Gottenberg, J.E.
- Haavardsholm, E.A.
- Iagnocco, A.
- Lauper, K.
- Li, Z.G.
- McInnes, I.B.
- Mysler, E.F.
- Nash, P.
- Poor, G.
- Ristic, G.G.
- Rivellese, F.
- Rubbert-Roth, A.
- Schulze-Koops, H.
- Stoilov, N.
- Strangfeld, A.
- Helm-van Mil, A. van der
- Duuren, E. van
- Vlieland, T.P.M.V.
- Westhovens, R.
- Heijde, D. van der
DOIAbstract
ObjectivesTo provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. MethodsAn international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned to and participants finally voted on the level of agreement with each item. ResultsThe task force agreed on 5 overarching principles and 11 recommendations concerning...
Add to ORKG